Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> or = 18 years of age~* Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG documentation)~* Able to swallow pill form of drug~Exclusion Criteria:~* \< 18 years of age~* enrollment in another ongoing trial~* paroxysmal atrial fibrillation~* hemodynamic instability~* atrial fibrillation ablation within 6 months of enrollment~* a contraindication for anticoagulation~* severe valvular heart disease~* presence of single lead implantable cardioverter defibrillator~* unstable angina~* New York Heart Association (NYHA) Class IV heart failure~* hyperthyroidism~* uncontrolled hypertension (blood pressure \> 180/100 at rest) on medications~* an illness that would limit life expectancy to less than 1 year~* use of statins within the previous 30 days~* significant coronary artery disease or lipid abnormalities necessitating statin therapy~* implanted devices for active management of arrhythmias by pacing or defibrillation~* lack of access to a telephone~* illicit drug use~* alcohol abuse~* hypersensitivity to atorvastatin by history~* pregnancy~* sexually active female subjects not on contraception or surgically sterilized~* nursing mothers~* chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the upper limit of normal \[ULN\] of laboratory reference range)~* severe renal disease (creatinine \> 200 mmol/L)~* inflammatory muscle disease or creatine kinase (CK) \> 3 times ULN~* concurrent treatment with cyclosporine, fibrates, or high-dose niacin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo taken daily
- Atorvastatin (Type: EXPERIMENTAL): Atorvastatin at a dose of 80 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).